Key result
Micra leadless pacemaker implantation linked to ~4% rate of new moderate to severe TR.
Why the study?
The potential risk of tricuspid regurgitation after leadless pacemaker implantation was not known.
Does leadless pacemaker implantation cause new-onset tricuspid regurgitation in patients requiring pacing?
Cross-Sectional (n=158)
Yes
Does leadless pacemaker implantation cause new-onset tricuspid regurgitation in patients requiring pacing?
Leadless pacemaker implantation may be associated with a small but clinically significant risk (~4%) of new-onset moderate-to-severe tricuspid regurgitation.
Answers are grounded in this paper and cite their sources.
May warrant post-implant tricuspid surveillance; leaves open causal risk versus transvenous leads.
Background Tricuspid regurgitation (TR) has been reported as a complication of transvenous pacemaker lead implantation. However, the potential risk of TR is not known in case of leadless devices. Purpose We describe a case series of moderate to severe TR following implantation of the leadless Micra device. Methods We performed a multicenter (n=6) cross-sectional survey across the United States and Italy. Patient data were obtained by chart review and only patients with baseline and follow-up echo Doppler data were included in this analysis. All images were reviewed by the first author. Results A total of 158 patients receiving Micra implant were screened of which 6 (3.8%) cases of moderate to severe TR were identified by the Doppler echo. The most common presenting symptom were shortness of breath (6/6, 100%) and fatigue (5/6, 83.3%). Prominent jugular venous pulsation was observed in 1/6 (16.7%) patients indicating severe TR. Median time to development of symptoms and detection of TR was 9±3 months. None of the 6 patients developed symptoms immediately after the procedure. Figure 1 illustrates severe TR in one of the six patients included in the study (off axis view). Conclusion In this small series, we observed new-onset moderate-severe TR following implantation of leadless device in approximately 4% of patients. Whether this is related to the positioning of the device, needs to be ascertained by future studies.
No takes yet. Share an insight, caveat, or question.
Fazia et al. (2023) conducted a cross-sectional in Patients receiving Micra implant (n=158). Leadless Micra pacemaker implantation was evaluated on Moderate to severe tricuspid regurgitation. Leadless Micra pacemaker implantation was associated with new-onset moderate to severe tricuspid regurgitation in 3.8% of patients.
Synapse has enriched 10 related papers. Consider them for comparative context: